Today’s Research Reports on Stocks to Watch: Genomic Health and Immunomedics

Genomic Health saw a major boost in trading price on Monday, with shares hitting a new high after encouraging results were published in The New England Journal of Medicine regarding data from the Trial Assigning Individualized Options for Treatment (TAILORx). The trial had found that about 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely pass on doing chemotherapy. Shares of Immunomedics also saw gains after announcing that it has entered into a clinical collaboration with Clovis Oncology.

RDI Initiates Coverage on:

Genomic Health, Inc.

Immunomedics, Inc.

Genomic Health, Inc. shares closed up a little over 23% yesterday on about 1.3 million shares traded. The stock hit a new high of $49.00 as investors cheered data from the Trial Assigning Individualized Options for Treatment (TAILORx) trial was presented at the American Society of Clinical Oncology meeting. The data was also published in The New England Journal of Medicine. TAILORx had followed over 10,000 women with breast cancer that was scored using Genomic Health’s Oncotype DX Breast Recurrence Score test. Roughly two-thirds of those had an intermediate score of 11 to 25; they were then treated with either hormone therapy alone, or hormone therapy plus chemotherapy. According to the results, women who were over 50 years old with the intermediate score could skip chemotherapy while women younger than 50 with a score lower than 15 could also skip it. This was due to chemo not offering any added benefit. The results also showed that women younger than 50 and a score of 16 to 25 benefited from adding chemotherapy. According to Dr. Steven Shak, chief scientific officer at Genomic Health, roughly 4 in 10 women in the United States with early stage breast cancers are not tested for recurrence risk. He expects the study’s results will change that practice. Shak remarked, "This is going to provide the highest level of evidence now for our test being indispensable in clinical practice."

Access RDI’s Genomic Health, Inc. Research Report at:

Immunomedics, Inc. shares closed up 10.26% on Monday with roughly 10.3 million shares traded. Immunomedics, one of the leading biopharmaceutical companies in the area of antibody-drug conjugates (ADC), revealed promising data for sacituzumab govitecan in patients heavily pretreated for metastatic estrogen receptor-positive breast cancer. The Company also released a comprehensive overview of its clinical development plan for its lead ADC, sacituzumab govitecan, at its Investor Event during the 2018 ASCO Annual Meeting. President and CEO, Michael Pehl, stated, “Our goal is to bring sacituzumab govitecan to patients who can benefit from this valuable drug candidate, expeditiously. Beyond TNBC, for which we recently announced our BLA submission, we are working closely with health authorities and key opinion leaders to define the best registrational approaches for additional indications that could benefit patients." The company also announced that it has entered into a clinical collaboration with Clovis Oncology to investigate a combination of two of the companies’ candidate treatments in a phase 1/2 study of patients that have metastatic triple-negative breast and urothelial cancers.

Access RDI’s Immunomedics, Inc. Research Report at:

Our Actionable Research on Genomic Health, Inc. (NASDAQ: GHDX) and Immunomedics, Inc. (NASDAQ: IMMU) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Nadia Noorani, CFA® charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.